OptiNose, Inc.

NasdaqGS OPTN

OptiNose, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -39.64 M

OptiNose, Inc. Operating Cash Flow is USD -39.64 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 12.14% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

OptiNose, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -45.12 M, a 32.34% change year over year.
OptiNose, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -66.69 M, a 15.99% change year over year.
OptiNose, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -79.38 M, a 6.79% change year over year.
OptiNose, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -85.16 M, a 8.34% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGS: OPTN

OptiNose, Inc.

CEO	Dr. Ramy A. Mahmoud M.D., M.P.H.
IPO Date	Oct. 13, 2017
Location	United States
Headquarters	1020 Stony Hill Road
Employees	132
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pollution Treatment

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Key trends

Past 5 years